Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC
出版年份 2022 全文链接
标题
Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC
作者
关键词
Neoadjuvant, NSCLC, TMB, PD-1 inhibitor, PD-L1 expression
出版物
Journal of Thoracic Oncology
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-05-10
DOI
10.1016/j.jtho.2022.04.012
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study
- (2022) Bolun Zhou et al. EBioMedicine
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial
- (2021) Corinne Faivre-Finn et al. Journal of Thoracic Oncology
- Lung Cancer in Republic of China
- (2021) Yung-Hung Luo et al. Journal of Thoracic Oncology
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
- (2021) Xiaoxiang Zhou et al. LANCET ONCOLOGY
- Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study
- (2021) Fan Zhang et al. Journal of Thoracic Disease
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
- (2020) Shugeng Gao et al. Journal of Thoracic Oncology
- Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches
- (2020) Dipesh Uprety et al. Journal of Thoracic Oncology
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis
- (2020) Xiao-hui Jia et al. LUNG CANCER
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
- (2019) Yuankai Shi et al. Lancet Haematology
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC
- (2019) Scott J. Antonia et al. Journal of Thoracic Oncology
- Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer
- (2018) Chi-Fu Jeffrey Yang et al. ANNALS OF THORACIC SURGERY
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy
- (2018) Si-Pei Wu et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
- (2018) Gideon M. Blumenthal et al. Journal of Thoracic Oncology
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery
- (2017) Michelle C. Salazar et al. JAMA Oncology
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
- (2015) Miklos Pless et al. LANCET
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
- (2015) S. H. Tirumani et al. Cancer Immunology Research
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy
- (2012) Apar Pataer et al. Journal of Thoracic Oncology
- Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer
- (2011) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma
- (2011) Ping Yang et al. Journal of Thoracic Oncology
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started